MSH2 and Lynch syndrome: In line with these results, a recently published survey conducted by the prospective Lynch Syndrome database (PLSD) show that most of the referral centers included worldwide (91–95%) offer RRGS to carriers of pathogenic variants in MLH1, MSH2 and MSH6 but less (67%) to carriers of pathogenic variants in PMS2. Most of the centers (71%) also recommend oestrogen-only HRT between 35-55 years, approximately [42].